Abstract
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Source: Autobound Signal API · 75 signals tracked for Incyte · updated
Get Incyte's live signals in Claude or ChatGPT, or by API
What changed at Incyte this week? Use Autobound signals for incyte.com.In October 2026 Incyte patented drug candidates for treating cancers and other diseases driven by the JAK2 V617F variant.
Abstract
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
What this signalsA new patent often shows where a company is putting its R&D budget.
Tags
Technologies named
patents-companypatentGrantGet every patent signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/43fbaa79-4763-5e1f-a707-a265c5850adc returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "43fbaa79-4763-5e1f-a707-a265c5850adc",
"signal_type": "patents-company",
"signal_subtype": "patentGrant",
"detected_at": "2026-10-14T15:26:56+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"cpc": [
{
"code": "C07D 471/14"
},
{
"code": "A61P 35/00"
}
],
"tags": [
"Intellectual Property",
"Research & Development",
"Pharmaceuticals",
"Medical Research"
],
"detail": "In October 2026 Incyte patented drug candidates for treating cancers and other diseases driven by the JAK2 V617F variant.",
"summary": "Incyte was granted a patent for compounds targeting JAK2 V617F.",
"event_at": "2026-10-13",
"inventors": [
{
"name": "Seoyoung Cho",
"status": "resolved",
"is_primary": true,
"linkedin_url": "https://www.linkedin.com/in/seoyoung-cho-b16074196"
},
{
"name": "Eddy W. Yue",
"status": "unresolved",
"is_primary": false
}
],
"event_kind": "grant_date",
"grant_date": "2026-10-13",
"source_url": "https://patents.google.com/patent/US12760022",
"cpc_primary": {
"code": "C07D 471/14"
},
"patent_title": "Tricyclic urea compounds as JAK2 V617F inhibitors",
"patent_number": "US12760022",
"uspto_assignee": "Incyte Corporation",
"patent_abstract": "The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.",
"precision_class": "structural",
"invention_explanation": "A class of tricyclic urea molecules designed to block the abnormal JAK2 activity associated with the V617F mutation.",
"technologies_mentioned": [
"JAK2 inhibitors",
"small-molecule drugs",
"cancer therapeutics"
]
}
}
curl https://signals.autobound.ai/v1/signals/43fbaa79-4763-5e1f-a707-a265c5850adc \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.